Tyra Biosciences, Inc. (Nasdaq: TYRA), a Califonia-based clinical-stage biotechnology company, announced on Thursday that it has received Rare Pediatric Disease (RPD) Designation from the US Food and Drug Administration (FDA) for its TYRA-300, an oral FGFR3 selective inhibitor, intended for the treatment of achondroplasia.
The company is planning to submit an Investigational New Drug application (IND) to the FDA in the second half of 2024 for the commencement of a randomised Phase two clinical trial assessing multiple dose cohorts of TYRA-300 for children with achondroplasia, the most common form of dwarfism with limited therapeutic options.
TYRA-300 is the company's lead precision medicine program stemming from its in-house SNÅP platform. TYRA-300 is an investigational, oral, FGFR3-selective inhibitor currently in development for the treatment of cancer and skeletal dysplasias, including achondroplasia. In oncology, TYRA-300 is being evaluated in a multi-centre, open label Phase 1/2 clinical study, SURF301 (Study in Untreated and Resistant FGFR3+ Advanced Solid Tumours).
Rare Pediatric Disease (RPD) Designation is granted by the FDA to investigational drugs and biologics designed to address serious or life-threatening diseases which affect fewer than 200,000 people in the United States, or for which there is no reasonable expectation that the cost of developing and making the drug or biologic available in the US for the applicable disease or condition will be recovered from sales in the US, and in which the serious or life-threatening manifestations primarily affect individuals less than 18 years of age.
Quest Diagnostics acquires OhioHealth lab assets
Exelixis and Merck collaborate on clinical development of zanzalintinib
BD launches automated reagent kit to streamline single-cell discovery studies
Transgene's Phase II trial of TG4001 falls short of primary objective
SkylineDx reveals new data from the MERLIN_001 prospective US multi-centre trial
Turnstone Biologics announces strategic restructuring
Pfizer's TALZENNA plus XTANDI shows promise in prostate cancer treatment
GenesisCare UK selects RayStation for radiotherapy system upgrade
Boehringer Ingelheim and Circle Pharma collaborate on cancer treatment
Petauri launches medical communications platform Petauri Advance
Bayer and MOMA Therapeutics enter oncology collaboration
GBI Biomanufacturing agrees manufacturing collaboration with Allterum Therapeutics
MediLink enters clinical trial collaboration and supply agreement with Amgen